Biological Treatment of Inflammatory Bowel Disease
dc.contributor.advisor | Pórszász, Róbert | |
dc.contributor.advisordept | Debreceni Egyetem::Általános Orvostudományi Kar::Farmakológiai és Farmakoterápiai Intézet | hu_HU |
dc.contributor.author | Mordehai, Orel-Guta Jr | |
dc.contributor.department | DE--Általános Orvostudományi Kar | hu_HU |
dc.contributor.opponent | Drimba, László | |
dc.contributor.opponent | Szentmiklósi, József András | |
dc.contributor.opponentdept | Kenézy Kórház Központi Aneszteziológiai és Intenzív Terápiás Osztály | hu_HU |
dc.contributor.opponentdept | Debreceni Egyetem::Általános Orvostudományi Kar::Farmakológiai és Farmakoterápiai Intézet | hu_HU |
dc.date.accessioned | 2018-09-26T09:41:10Z | |
dc.date.available | 2018-09-26T09:41:10Z | |
dc.date.created | 2017-04-28 | |
dc.description.abstract | IBD is an idiopathic, chronic inflammation resulting from UC or CD. During the last decades biological therapy revolutionized the treatment options for moderate to severe CD and UC that is refractory to conventional treatment. . These monoclonal antibodies, which target TNF, integrins or IL12/23, have been approved for IBD. | hu_HU |
dc.description.corrector | hbk | |
dc.description.course | általános orvos | hu_HU |
dc.description.courselang | angol | hu_HU |
dc.description.degree | egységes, osztatlan | hu_HU |
dc.format.extent | 58 | hu_HU |
dc.identifier.uri | http://hdl.handle.net/2437/257245 | |
dc.language.iso | en | hu_HU |
dc.subject | IBD | hu_HU |
dc.subject | Inflammatory boweldiseases | |
dc.subject | Crohn’s diseas ulcerative colitis | |
dc.subject | tumor necrosis factor | |
dc.subject | anti-integrin | |
dc.subject | interleukin(IL)-23/IL-1 | |
dc.subject | Biological treatment | |
dc.subject | Infliximab | |
dc.subject | adalimumab | |
dc.subject | Certolizumab pegol | |
dc.subject | Golimumab | |
dc.subject | Natalizumab | |
dc.subject | Vedolizumab | |
dc.subject | Ustekinumab | |
dc.subject.dspace | DEENK Témalista::Orvostudomány | hu_HU |
dc.title | Biological Treatment of Inflammatory Bowel Disease | hu_HU |